Biotransformation of topotecan in the isolated perfused rat liver: Identification of three novel metabolites

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2695-2700

  Platzer, Peter ^a   Schaden, Sabine ^a   Thalhammer, Therese ^a   Hamilton, Gerhard ^b   Rosenberg, Bernd ^c   Silgoner, Ingo ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Glucuronides; Metabolism; Rat liver; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; DRUG METABOLITE; TOPOTECAN;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; ISOLATED LIVER; LIVER PERFUSION; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONATES; KINETICS; LIVER; MALE; MOLECULAR STRUCTURE; PERFUSION; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOPOTECAN;

EID: 0031839973     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. I. The isolation and structure of camptothecins, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
2. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461 - 470, 1970.
3. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
4. Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
5. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating M, Estey EH: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81: 1146-1151, 1993.
6. Sinha BK: Topoisomerase inhibitors - a review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995.
7. Herben VMM, ten Bokkel Huinik WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31: 85-102, 1996.
8. Underberg WJM, Goossen RMJ, Smith BR: Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8: 681 -683, 1990.
9. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJC: An overview of the clinical pharmacology of topotecan. Semin Oncol 24 (1, Suppl 5): S5-12 - S5-18, 1997.
10. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A (6): 921 -926, 1996.
11. Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F: Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 3: 955-961, 1997.
12. Rosing H, Herben VMM, van Gortel-van Zomeren DM, Hop E, Kettenes-van den Bosch JJ, ten Bokkel Huinink WW, Beijnen JH: Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 39: 498-504, 1997.
13. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB: Clinical pharmacodynamics of continuous topotecan infusion in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12: 1946, 1994.
14. Rivory LP, Robert J: Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176-179, 1995.
15. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J: Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 80: 91-96, 1997.
16. Thalhammer T, Stapf V, Gadzik L, Graf J: Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Europ J Pharmacol 270: 213-220, 1994.
17. Lokiec F, Monegier du Sorbier B, Sanderink GJ: Irinotecan (CPT-11) metabolism in human bile and urine. Clin Cancer Res 2: 1943-1949, 1996.